Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estradiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 5/20 | 0.89 |
| ▸ | LMNA | P02545 | 5/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.89 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | STS | P08842 | 2/20 | 0.89 |
| ▸ | PGR | P06401 | 2/20 | 0.89 |
| ▸ | AR | P10275 | 2/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.89 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.89 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.89 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfatradiol SCHEMBL504619 | 1.00 | ESR1 (0.89) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL504620 | 1.00 | ESR1 (0.89) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL28291281 | 0.99 | HSD17B10 (0.87) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL6409242 | 0.99 | HSD17B10 (0.87) | ESR1LMNAHSD17B10ESR2TSHR | |
| Alfatradiol SCHEMBL14562872 | 0.99 | HSD17B10 (0.87) | ESR1LMNAHSD17B10ESR2TSHR | |
| Alfatradiol SCHEMBL28291280 | 0.99 | HSD17B10 (0.87) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL628175 | 0.96 | ESR1 (0.85) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL24037697 | 0.94 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL7037626 | 0.94 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL19235633 | 0.94 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2317995-B1 | INHBITORS OF MRP4 AND AGENTS STIMULATING MRP4 ACTIVITY FOR THE TREATMENT OF CARDIAC DISORDERS | INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) (FR) | 2016-12-07 | — | — | EP | claimed |
| EP-1898894-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2008-03-19 | — | — | EP | claimed |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | US | claimed |
| WO-2006134022-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | WO | claimed |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | VAN BOGAERT GINA (BE) | 2026-01-15 | — | — | US | disclosed |
| EP-4103160-B1 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | ETH ZUERICH (CH) | 2024-06-26 | — | — | EP | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023223235-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | PURNA PHARMACEUTICALS NV (BE) | 2023-11-23 | — | — | WO | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | US | disclosed |
| WO-2006134022-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060258861-A1 | Respiratory or gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| WO-2006114371-A1 | NOVEL COMPOUNDS FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006111549-A1 | DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| EP-1151295-A4 | METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS | CYTOVIA INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1151295-A1 | METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS | Cytovia, Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000045165-A1 | METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS | CYTOVIA, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258861-A1 | Respiratory or gastrointestinal disorders; cancer | CYP2E1, UGT1A1, SLC26A4 | ESR1 4081/4885LMNA 3654/4885HSD17B10 426/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ESR1 1884/4885LMNA 4656/4885HSD17B10 1825/4885 |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | NR5A1, SHBG, GNRHR | ESR1 188/4885LMNA 796/4885HSD17B10 448/4885 |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | ABCB1, ABCC4, ABCC1 | ESR1 4183/4885LMNA 1165/4885HSD17B10 1406/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ESR1 3891/4885LMNA 3018/4885HSD17B10 3587/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | ESR1 1884/4885LMNA 4656/4885HSD17B10 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.